Eurobio France 2009. European showcase for biotechnologies.
Lille, December 2009.- Like the salons Bio US ” and Bio Japan ”, European EuroBio is an event of required assistance to the international biotechnology community. The 2009 Edition has taken place, at the end of September, in the French city of Lille.
The year’s last, held in Paris, received the visit of 5,000 participants from 20 countries, 120 lecturers of international prestige and approximately 500 exhibitors (companies and clusters).
Annual meeting between industry and researchers at EuroBio covered key aspects of various biotechnological applications (health, agriculture and industry), which represents a unique opportunity to learn about advances in r & d, and assess the economic situation of a primary sector both mankind and the environment.
Health is the sector in which biotechnology has a greater impact. France occupies the third position in Europe, after the United Kingdom and Germany.
Enterprises biotechnological French, such as Bio-Alliance, Nicox, ExonHit, Hybrigenics, are characterized by its innovation and cutting-edge research thanks to the count, in some cases, with the backing of big pharmaceutical groups, able to fund costosÃsimos projects of r & d.
Other pioneers in the field of biotechnology such as Amgen, Genentech and Genzyme, have become signatures biopharmaceutical ” marketed medicines. This new strategic orientation is of vital importance, given that the majority of future drugs will be developed through biotechnology.
Since 2005, eight clusters, located in different French regions, have focused their activities in the sectors of biotechnology and health, thereby boosting the exchange of knowledge between manufacturers and laboratories of the public sector: Lyonbiopôle (Rhône), Medicen (Ile-de-France), Alsace BioValley (Alsace), Nutrition Health Longevity (Nord-Pas-de-Calais)Atlantic Biotherapies (Pays de la Loire), Prod ’ Innov (Aquitaine), EuroBioMed (Languedoc-Roussillon in southern France/Provence – Côte d’Azur) and Cancer-Bio-Santé (Midi-Pyrénées).
This important development has its origins in the French health research, which was recognized last year by the granting of the Nobel Prize in medicine in 2008 to the teachers Françoise Barré-Sinoussi and Luc Montagnier of the Pasteur Institute in Paris, discoverers of the virus of human immunodeficiency (HIV). Meanwhile in the Génopôle d ’ Evry – campus dedicated to biotechnology –, Jean Weissenbach, Director of Génoscope, established the first high resolution of the human genome map.
In addition, entities of the biotechnology sector r & d departments now have the support of one of the programs of tax credits for research more attractive in Europe. Main reason why CellSeed, Japanese biotechnology company specializing in stem cell therapy, has decided to establish in Lyon, attracted both by the quality of their platforms of clinical trials, transparency of the regulatory framework, ethics, and relationship with the patient, as by the widespread availability of experts.
David Appia, Chairman of Scoreboard, says, En France, health is a national priority, and new drugs to increase the use of biotechnology. This country is currently at the forefront of the European biotechnology sector and possesses all the attributes for that biotechnology companies – many of them SMEs –, opt to settle in any of the 8 clusters of innovation, which generate dynamic ecosystems given business with the best European research tax credits program. All this is part of the efforts of the professionals of the sector and major pharmaceutical companies in pursuit of innovation.
About ….
Scoreboard, French Agency for international investment deals with both promoting, prospecting, as the channelling of international investment. It also promotes projects and facilitates investment in France. Scoreboard is the economic organism of reference for the recruitment of potential customers and the image of France. Structured in a network that operates at international, national and territorial levels, it works closely with the French regional economic development agencies in order to provide a personalized service to international investors.
